GSK's concedes defeat over MAGE-A3 in lung cancer
This article was originally published in Scrip
Executive Summary
GlaxoSmithKline has decided to drop its MAGE-A3 cancer vaccine in non-small cell lung cancer (NSCLC). The Phase III MAGRIT trial of MAGE-A3 is being terminated as it "will not be possible to identify a sub-population of gene-signature positive NSCLC patients that may benefit from the treatment," said GSK.
You may also be interested in...
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Pfizer/Astellas Amend Trial To Position Xtandi In Early Prostate Cancer
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.